In April this year Mymetics has started a Covid-19 vaccine development project based on Mymetics’ virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.
In May 2020 Mymetics and Baylor College of Medicine in Texas signed a Research Agreement to preclinically produce and test virosomes incorporating SARS-CoV-2 recombinant proteins.
As part of the Research Agreement, Mymetics has successfully produced several virosome vaccine formulations that will now be tested in a preclinical model at Baylor College of Medicine.
Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today as part of the Research Agreement signed in May 2020 with Baylor College of Medicine and Texas Children’s Center for Vaccine Development, that Mymetics has piloted and successfully produced different virosome formulations which incorporate the SARS-CoV-2 recombinant protein. The company has now shipped these formulations to Baylor College of Medicine where they will be tested and compared in a pre-defined preclinical model in accordance with the Research Agreement signed between the parties in May 2020. Results are expected in three months.
Since the end of April, Mymetics has started a project for the rapid development of a Covid-19 virosome-based vaccine and is partnering with leading academic institutions to explore and select the best SARS-CoV antigens, which could not only be efficacious in protecting against Covid-19 but are also safe, easy to administer and dose sparing. Additional preclinical studies at other sites will be announced in the coming weeks.